| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/JPET.110.173948 |
| P953 | full work available online at | http://intl-jpet.aspetjournals.org/cgi/content/abstract/336/2/296 |
| https://syndication.highwire.org/content/doi/10.1124/jpet.110.173948 | ||
| P698 | PubMed publication ID | 21030484 |
| P2093 | author name string | Terry Kenakin | |
| P2860 | cites work | A modification of receptor theory | Q24553119 |
| Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo | Q24647416 | ||
| beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice | Q24654027 | ||
| Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors | Q24681428 | ||
| Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase | Q28218669 | ||
| Agonist-specific regulation of the delta-opioid receptor | Q28295395 | ||
| Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse | Q28297001 | ||
| Nicotinic acid receptor agonists differentially activate downstream effectors | Q28298974 | ||
| Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes | Q28375923 | ||
| Enhanced morphine analgesia in mice lacking beta-arrestin 2 | Q28504554 | ||
| The Energy Landscapes and Motions of Proteins | Q29616408 | ||
| Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. | Q30476292 | ||
| Single-molecule spectroscopy of the beta(2) adrenergic receptor: observation of conformational substates in a membrane protein | Q30994408 | ||
| A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. | Q33779634 | ||
| Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 | ||
| Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. | Q34134694 | ||
| Aripiprazole | Q34203550 | ||
| Efficacy as a vector: the relative prevalence and paucity of inverse agonism | Q34289691 | ||
| Agonist-receptor efficacy. II. Agonist trafficking of receptor signals | Q34304785 | ||
| Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. | Q34536660 | ||
| An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization | Q34580057 | ||
| A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. | Q34588487 | ||
| Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance | Q34650437 | ||
| Beta-arrestin-biased ligands at seven-transmembrane receptors | Q34654662 | ||
| The role of incretins in glucose homeostasis and diabetes treatment | Q34901533 | ||
| Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes | Q35133773 | ||
| Ligand-selective receptor conformations revisited: the promise and the problem | Q35181787 | ||
| Beta-blockers in heart failure: are pharmacological differences clinically important? | Q35934100 | ||
| A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling | Q36082162 | ||
| Multiple signaling states of G-protein-coupled receptors | Q36138102 | ||
| Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors | Q36160942 | ||
| New concepts in drug discovery: collateral efficacy and permissive antagonism | Q36303814 | ||
| When 7 transmembrane receptors are not G protein-coupled receptors | Q36308861 | ||
| A statistical thermodynamic model of the protein ensemble | Q36472751 | ||
| GPCR functional selectivity has therapeutic impact | Q36880909 | ||
| Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. | Q36880915 | ||
| Pharmacological onomastics: what's in a name? | Q36911200 | ||
| Estimation of relative microscopic affinity constants of agonists for the active state of the receptor in functional studies on M2 and M3 muscarinic receptors | Q37199106 | ||
| Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling | Q37209196 | ||
| Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands | Q37210835 | ||
| Molecular determinants of angiotensin II type 1 receptor functional selectivity | Q37291841 | ||
| Physiological and pharmacological implications of beta-arrestin regulation. | Q37356068 | ||
| '7TM receptor allostery: putting numbers to shapeshifting proteins | Q37591623 | ||
| Multiple mechanisms of serotonergic signal transduction | Q38177519 | ||
| Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. | Q39749438 | ||
| Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity | Q39884754 | ||
| Multiplexed assays by high-content imaging for assessment of GPCR activity | Q39976157 | ||
| Signaling through a G Protein-coupled receptor and its corresponding G protein follows a stoichiometrically limited model | Q40147596 | ||
| Resonant waveguide grating biosensor for living cell sensing. | Q40269125 | ||
| G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer | Q40281519 | ||
| Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy | Q40298849 | ||
| Molecular mechanisms of membrane receptor desensitization. | Q40491298 | ||
| Selective signaling via unique M1 muscarinic agonists | Q40779652 | ||
| Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo | Q40948644 | ||
| Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. | Q41842236 | ||
| Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. | Q42937057 | ||
| Subtype specific roles of beta-adrenergic receptors in apoptosis of adult rat ventricular myocytes | Q44051395 | ||
| H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway | Q44956223 | ||
| Analysis of allosterism in functional assays | Q46171612 | ||
| Morphine side effects in beta-arrestin 2 knockout mice | Q46510708 | ||
| New strategies in drug discovery for GPCRs: high throughput detection of cellular ERK phosphorylation | Q46553254 | ||
| Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus | Q47866757 | ||
| Agonist efficacy and allosteric models of receptor action. | Q52264097 | ||
| Conformational changes and drug action | Q70973331 | ||
| Pharmacological basis for functional selectivity of partial muscarinic receptor agonists | Q71149990 | ||
| Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2 | Q81391001 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bias | Q742736 |
| P304 | page(s) | 296-302 | |
| P577 | publication date | 2010-10-28 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Functional selectivity and biased receptor signaling | |
| Functional Selectivity and Biased Receptor Signaling | |||
| P478 | volume | 336 |
| Q34321618 | A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine |
| Q53819121 | A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action |
| Q36835278 | A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models |
| Q47070511 | A comparison of the signalling properties of two tyramine receptors from Drosophila |
| Q61797498 | A conserved molecular switch in Class F receptors regulates receptor activation and pathway selection |
| Q33880430 | A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer |
| Q35531857 | A novel method for analyzing extremely biased agonism at G protein-coupled receptors |
| Q34552020 | A review of perioperative anesthesia and analgesia for infants: updates and trends to watch |
| Q90702264 | A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor |
| Q36299381 | AIM for Allostery: Using the Ising Model to Understand Information Processing and Transmission in Allosteric Biomolecular Systems. |
| Q36593223 | Activation of c-SRC underlies the differential effects of ouabain and digoxin on Ca2+ signaling in arterial smooth muscle cells |
| Q63707053 | Activation of the calcium-sensing receptor in human valvular interstitial cells promotes calcification |
| Q36283874 | Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling |
| Q42747954 | Agonist ligand discrimination by the two orexin receptors depends on the expression system |
| Q36299173 | Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation |
| Q34543233 | Allosteric Modulation of Protease-Activated Receptor Signaling |
| Q38847270 | Allosteric Modulators of the Class A G Protein Coupled Receptors |
| Q38209745 | Amphipols in G protein-coupled receptor pharmacology: what are they good for? |
| Q35122853 | Analysis of Agonism and Inverse Agonism in Functional Assays with Constitutive Activity: Estimation of Orthosteric Ligand Affinity Constants for Active and Inactive Receptor States |
| Q35122845 | Analysis of Functional Responses at G Protein-Coupled Receptors: Estimation of Relative Affinity Constants for the Inactive Receptor State |
| Q38429608 | Approaches to Assess Biased Signaling at the CB1R Receptor. |
| Q37504309 | Association of Cell Adhesion Molecules Contactin-6 and Latrophilin-1 Regulates Neuronal Apoptosis |
| Q42047360 | Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites |
| Q34036456 | Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells |
| Q64097803 | Biased Signaling and Allosteric Modulation at the FSHR |
| Q64087686 | Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons |
| Q38209355 | Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective. |
| Q38678404 | Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery? |
| Q38440471 | Biased agonism: An emerging paradigm in GPCR drug discovery |
| Q34795759 | Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics |
| Q35351711 | Biased signaling at chemokine receptors |
| Q38214613 | Biased signaling of protease-activated receptors |
| Q35752199 | Biased signaling: potential agonist and antagonist of PAR2. |
| Q37948862 | Biased signalling and allosteric machines: new vistas and challenges for drug discovery |
| Q37635262 | Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. |
| Q47616908 | Bioluminescence Resonance Energy Transfer Assay to Characterize Gi-Like G Protein Subtype-Dependent Functional Selectivity. |
| Q38812508 | Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. |
| Q33833528 | CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling |
| Q34186015 | CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? |
| Q48137701 | Calcium receptor signaling and citrate transport. |
| Q26851297 | Calcium sensing receptor signalling in physiology and cancer |
| Q34350478 | Casting a Wider Net: Whole-Cell Assays to Capture Varied and Biased Signaling: Fig 1 |
| Q47437537 | Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603. |
| Q34415488 | Characterization of a prawn OA/TA receptor in Xenopus oocytes suggests functional selectivity between octopamine and tyramine |
| Q92359520 | Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT1 and MT2 receptors |
| Q34169978 | Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. |
| Q48127796 | Comparison of the Human A2A Adenosine Receptor Recognition by Adenosine and Inosine: New Insight from Supervised Molecular Dynamics Simulations |
| Q92355525 | Conformational plasticity of the intracellular cavity of GPCR-G-protein complexes leads to G-protein promiscuity and selectivity |
| Q53281321 | Critical Role for Gi/o-Protein Activity in the Dorsal Striatum in the Reduction of Voluntary Alcohol Intake in C57Bl/6 Mice. |
| Q92968450 | D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine |
| Q39341454 | Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. |
| Q38129685 | Defining and characterizing drug/compound function |
| Q39062836 | Delta Opioid Receptors: Learning and Motivation |
| Q37179419 | Delta opioid receptors in brain function and diseases |
| Q39204577 | Detailed analysis of biased histamine H₄ receptor signalling by JNJ 7777120 analogues |
| Q39527452 | Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). |
| Q89892013 | Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists |
| Q34231629 | Differential activation of cAMP- and cGMP-dependent protein kinases by cyclic purine and pyrimidine nucleotides |
| Q39421211 | Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues |
| Q37625769 | Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats |
| Q34327895 | Discovery of Regulators of Receptor Internalization with High-Throughput Flow Cytometry |
| Q41137764 | Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders |
| Q36949575 | Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors |
| Q37323725 | Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells |
| Q33619504 | Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR) |
| Q38214620 | Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization. |
| Q47881237 | Editorial: Are all eotaxins created equal? |
| Q38669392 | Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype. |
| Q41923007 | Endogenous Ouabain: Recent Advances and Controversies |
| Q36105495 | Endomorphin-2: a biased agonist at the μ-opioid receptor. |
| Q26767156 | Endothelin |
| Q37635257 | Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders |
| Q35851621 | Ensemble of G Protein-Coupled Receptor Active States |
| Q33638068 | Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias |
| Q37999097 | Evidence from basic research for opioid combinations |
| Q34837191 | Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling |
| Q29147543 | Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation |
| Q42407015 | Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway |
| Q39509078 | Functional reconstitution of human neuropeptide Y (NPY) Y(2) and Y(4) receptors in Sf9 insect cells. |
| Q35264421 | Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. |
| Q38017279 | Functional selectivity in GPCR heterocomplexes. |
| Q38200337 | Functional selectivity of GPCR signaling in animals |
| Q36598545 | Functional selectivity of adenosine A1 receptor ligands? |
| Q37872220 | Functional selectivity of adenosine receptor ligands |
| Q38017282 | Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics. |
| Q35154034 | Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers |
| Q46308914 | G Protein-Coupled Receptor Endocytosis Confers Uniformity in Responses to Chemically Distinct Ligands |
| Q26741203 | G Protein-Coupled Receptors in Cancer |
| Q41367745 | G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning |
| Q35095000 | G protein-coupled receptor signaling analysis using homogenous time-resolved Förster resonance energy transfer (HTRF®) technology |
| Q64245124 | G-Protein-Coupled Receptors Are Dynamic Regulators of Digestion and Targets for Digestive Diseases |
| Q58568628 | GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures |
| Q34398651 | Ghrelin and motilin receptor agonists: time to introduce bias into drug design |
| Q57918892 | GnRH Action |
| Q58554121 | HBK-17, a 5-HT Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling |
| Q24595389 | Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model |
| Q44346034 | Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen |
| Q49901474 | Imaging corticotropin-releasing-factor and nociceptin in addiction and PTSD models |
| Q28478728 | Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles |
| Q92404339 | Impedance-based analysis of mu opioid receptor signaling and underlying mechanisms |
| Q64927257 | Implications of Off-Target Serotoninergic Drug Activity: An Analysis of Serotonin Syndrome Reports Using a Systematic Bioinformatics Approach. |
| Q87849905 | Increased Gi protein signaling potentiates the negative chronotropic effect of adenosine in the SHR right atrium |
| Q58428295 | Increasing the flexibility of the LANCE cAMP detection kit |
| Q38760567 | Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors. |
| Q48812098 | Interactions of recombinant human histamine H1, H2, H3, and H4 receptors with 34 antidepressants and antipsychotics |
| Q26827568 | International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors |
| Q34770179 | Inverse Agonist and Pharmacochaperone Properties of MK-0524 on the Prostanoid DP1 Receptor |
| Q38810731 | Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors |
| Q33595477 | Label-free cell phenotypic profiling decodes the composition and signaling of an endogenous ATP-sensitive potassium channel |
| Q36274247 | Large-scale bioactivity analysis of the small-molecule assayed proteome |
| Q38077231 | Ligand bias at the μ-opioid receptor |
| Q38445448 | Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators. |
| Q28477403 | Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target |
| Q36382935 | Ligand-directed signalling within the opioid receptor family |
| Q34573953 | Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5. |
| Q30842363 | Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe |
| Q34139164 | Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays |
| Q38096004 | Measurement of G protein-coupled receptor surface expression. |
| Q39335768 | Measurements of β-Arrestin Recruitment to Activated Seven Transmembrane Receptors Using Enzyme Complementation |
| Q36947742 | Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor |
| Q36903579 | Membrane modulates affinity for calcium ion to create an apparent cooperative binding response by annexin a5 |
| Q37050373 | Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery |
| Q47562869 | Modelling and simulation of biased agonism dynamics at a G protein-coupled receptor. |
| Q51603766 | Molecular Dynamics Simulations of G Protein-Coupled Receptors |
| Q37573308 | Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer |
| Q39458009 | Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics? |
| Q38773802 | Multilayered proteomics reveals molecular switches dictating ligand-dependent EGFR trafficking |
| Q36115098 | Multiple ligand-specific conformations of the β2-adrenergic receptor |
| Q39093865 | Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). |
| Q38044984 | New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. |
| Q26864286 | Novel GPCR paradigms at the μ-opioid receptor |
| Q27026973 | Nuclear GPCRs in cardiomyocytes: an insider's view of β-adrenergic receptor signaling |
| Q49270407 | Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System |
| Q34729984 | Opioid receptor desensitization: mechanisms and its link to tolerance |
| Q38085387 | Opioid receptor interacting proteins and the control of opioid signaling. |
| Q26859602 | Opportunities for functional selectivity in GPCR antibodies |
| Q37522864 | Orexin/hypocretin receptor signalling: a functional perspective |
| Q37851695 | Orthologue selectivity and ligand bias: translating the pharmacology of GPR35 |
| Q51242223 | Parathyroid Hormone (PTH) and PTH-Related Peptide Domains Contributing to Activation of Different PTH Receptor–Mediated Signaling Pathways |
| Q48193375 | Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5. |
| Q34571419 | Pathway-selective antagonism of proteinase activated receptor 2. |
| Q37893687 | Pharmacological modulation of chemokine receptor function. |
| Q61124865 | Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects |
| Q26822470 | Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 |
| Q39573600 | Plant lectins are novel Toll-like receptor agonists |
| Q27027736 | Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications |
| Q35672413 | Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor. |
| Q39323119 | Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer |
| Q38966192 | Proteinases, Their Extracellular Targets, and Inflammatory Signaling. |
| Q28647166 | Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection |
| Q53171010 | Quantifying biased signaling in GPCRs using BRET-based biosensors |
| Q36763815 | Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection |
| Q38172958 | Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents? |
| Q37597891 | Racemic Salsolinol and its Enantiomers Act as Agonists of the μ-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway |
| Q42009313 | Regulation of G Protein-Coupled Receptors by Ubiquitination |
| Q36591603 | Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. |
| Q39136506 | Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor |
| Q38173201 | Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy |
| Q42177785 | Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors |
| Q36157679 | Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2. |
| Q38081692 | Signalling bias in new drug discovery: detection, quantification and therapeutic impact. |
| Q41906281 | Signalling profile differences: paliperidone versus risperidone |
| Q30544125 | Simulations of biased agonists in the β(2) adrenergic receptor with accelerated molecular dynamics |
| Q47344641 | Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence |
| Q38011697 | Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor |
| Q34012132 | Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3 |
| Q26744084 | Specialized Functional Diversity and Interactions of the Na,K-ATPase |
| Q36934953 | Species differences in the effects of the κ-opioid receptor antagonist zyklophin |
| Q36573973 | Stalk-dependent and Stalk-independent Signaling by the Adhesion G Protein-coupled Receptors GPR56 (ADGRG1) and BAI1 (ADGRB1) |
| Q35747694 | Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor |
| Q27676930 | Structural Features for Functional Selectivity at Serotonin Receptors |
| Q90391744 | Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21 |
| Q38895025 | Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling |
| Q37854213 | Structural insights into adrenergic receptor function and pharmacology |
| Q37896916 | Structural insights into agonist-induced activation of G-protein-coupled receptors |
| Q30382524 | Structure and function of serotonin G protein-coupled receptors. |
| Q37062531 | Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor |
| Q43803673 | Study of structural dynamics of ligand-activated membrane receptors by means of principal component analysis |
| Q26800056 | Studying GPCR/cAMP pharmacology from the perspective of cellular structure |
| Q94521819 | TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome |
| Q35197000 | Targeted intestinal epithelial deletion of the chemokine receptor CXCR4 reveals important roles for extracellular-regulated kinase-1/2 in restitution |
| Q34628609 | Targeting pro-resolution pathways to combat chronic inflammation in COPD |
| Q37972789 | Targeting proteinase-activated receptors: therapeutic potential and challenges. |
| Q28084125 | Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date |
| Q58738814 | Telocinobufagin and Marinobufagin Produce Different Effects in LLC-PK1 Cells: A Case of Functional Selectivity of Bufadienolides |
| Q57147941 | The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures |
| Q38874828 | The Multiple Waves of Cannabinoid 1 Receptor Signaling |
| Q35264433 | The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery |
| Q36973488 | The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. |
| Q47685791 | The development of label-free cellular assays for drug discovery |
| Q92359530 | The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion |
| Q39086835 | The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain |
| Q35182082 | The long pentraxin PTX3 promotes fibrocyte differentiation |
| Q38176658 | The multitarget drug approach in migraine treatment: the new challenge to conquer |
| Q34402658 | The potential for selective pharmacological therapies through biased receptor signaling |
| Q36287728 | The role of the dynorphin/κ opioid receptor system in anxiety |
| Q24288817 | The search for novel analgesics: targets and mechanisms |
| Q34371660 | The serotonin 5-HT7 receptors: two decades of research |
| Q38050536 | The signaling pathways of LMX1B and its role in glomerulosclerosis |
| Q37911818 | Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure |
| Q58604383 | Translational potential of allosteric modulators targeting the cannabinoid CB receptor |
| Q24635233 | Understanding Molecular Recognition by G protein βγ Subunits on the Path to Pharmacological Targeting |
| Q36300230 | Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease |
| Q99593506 | Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with Bioluminescence Resonance Energy Tranfer |
| Q26852233 | Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs |
| Q41767436 | Update on the urotensinergic system: new trends in receptor localization, activation, and drug design |
| Q37999094 | Using label-free screening technology to improve efficiency in drug discovery |
| Q92409897 | Utilization of Biased G Protein-Coupled ReceptorSignaling towards Development of Safer andPersonalized Therapeutics |
| Q30366876 | VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy |
| Q30395265 | Vibrational resonance, allostery, and activation in rhodopsin-like G protein-coupled receptors |
| Q38082094 | What Ligand-Gated Ion Channels Can Tell Us About the Allosteric Regulation of G Protein-Coupled Receptors |
| Q30386356 | i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4. |
| Q36083423 | ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands. |
| Q38791742 | β2 Agonists |
| Q51009893 | β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity? |
Search more.